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Abstract 
Aflapin
® is a novel synergistic composition derived from Boswellia serrata gum resin (Indian 
Patent Application No. 2229/CHE/2008). Aflapin is significantly better as an anti-inflammatory 
agent  compared  to  the  Boswellia  extracts  presently  available  in  the  market.  A  90-day, 
double-blind, randomized, placebo-c o n t r o l l e d   s t u d y   w a s   c o n d u c t e d   t o   e v a l u a t e   t h e   c o m-
parative efficacy and tolerability of 5-Loxin
® and Aflapin
® in the treatment of osteoarthritis 
(OA) of the knee (Clinical trial registration number: ISRCTN80793440). Sixty OA subjects 
w e r e   i n c l u d e d   i n   t h e   s t u d y .   T h e   s u b j e c t s   r e c e i v e d   e i t h e r   1 0 0   m g   ( n = 2 0 )   o f   5 -Loxin
® o r   1 0 0   m g  
(n=20) of Aflapin
® or a placebo (n=20) daily for 90 days. Each patient was evaluated for pain 
and physical functions by using the standard tools (visual analog scale, Lequesne's Functional 
Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline 
(day 0), and at days 7, 30, 60 and 90. A battery of biochemical parameters in serum, urine and 
hematological parameters in citrated whole blood were performed to assess the safety of 
5-Loxin
® and Aflapin
® i n   O A   s u b j e c t s .   F i f t y   s e v e n   s u b j e c t s   c o m p l e t e d   t h e   s t u d y .   A t   t h e   e n d   o f  
the  study,  both  5-Loxin
®  and  Aflapin  conferred  clinically  and  statistically  significant  im-
provements in pain scores and physical function scores in OA subjects. Interestingly, signifi-
cant improvements in pain score and functional ability were recorded as early as 7 days after 
i n i t i a t i o n   o f   t h e   s t u d y   i n   t h e   t r e a t m e n t   g r o u p   s u p p l e m e n t e d   w i t h   1 00 mg Aflapin. Corrobo-
rating the improvements in pain scores in treatment groups, our in vitro studies  provide 
evidences that Aflapin
® is capable of inhibiting cartilage degrading enzyme MMP-3 and has the 
potential to regulate the inflammatory response by inhibiting ICAM-1. Aflapin
® and 5-Loxin
® 
reduce pain and improve physical functions significantly in OA subjects. Aflapin exhibited 
better efficacy compared to 5-Loxin
®.   I n   c o m p a r i s o n   w i t h   p l a c e b o ,   t h e   s a f e t y   p a r a m e t e r s  
were almost unchanged in the treatment groups. Hence both 5-Loxin
® and Aflapin
® are safe 
for human consumption. 
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Introduction 
Osteoarthritis  (OA)  is  the  commonest  form  of 
arthritic disease, characterized by articular cartilage 
degradation  with  an  accompanying  peri-articular 
b o n e   r e s p o n s e   [ 1 , 2 ] .   O A   a f f e c t s   n e a r l y   2 1   m i l l i o n  
p e o p l e   i n   t h e   U S A ,   a c c o u n t i n g   f o r   2 5 %   o f   v i s i t s   t o  
p r i m a r y   c a r e   p h y s i c i a n s .   I t   i s   e s t i m a t e d   t h a t   8 0 %   o f  
the population will have radiographic evidence of OA 
b y   a g e   6 5   y e a r s ,   a l t h o u g h   o n l y   6 0 %   o f   t h o s e   w i l l   b e  
symptomatic [3]. Clinical manifestations of OA of the 
knee include pain in and around the joint, stiffness of 
t h e   j o i n t ,   c r e p i t a t i o n   o n   m o t i o n   a n d   l i m i t e d   j o i n t   m o-
tion, among others [4]. Current recommendations for 
managing OA focus on relieving pain and stiffness 
and improving physical function as important goals 
of therapy [5,6]. Currently available medication re-
gimens for most cases include nonopioid analgesics 
such  as  acetaminophen  and  nonsteroidal  an-
ti-inflammatory  drugs  (NSAIDs)  including  cyc-
lo-oxygenase  II  inhibitors.  These  pharmaceutical 
agents can reduce both pain and inflammation quite 
e f f e c t i v e l y ,   b u t   l o n g   t e r m   u s e   o f   N S A I D s   h a s   b e e n  
found to associate with enhanced risk for gastrointes-
tinal bleeding, hypertension, congestive heart failure 
and renal insufficiency, among other adverse effects 
[7-9]. Because of the high incidence of adverse events 
associated  with  both  nonselective  and  cyc-
lo-oxygenase  II  selective  NSAID  therapy,  effective 
and safer alternative treatments for OA are urgently 
needed. In recent years, the gum resin extracted from 
the  ancient  herb,  Boswellia serrata  has  gained  lot  of 
attention as a potent anti-inflammatory, anti-arthritic 
and analgesic agent [10,11]. 3-O-acetyl-11-keto-beta- 
boswellic acid (AKBA) is the most active component 
of Boswellia extract and has been demonstrated to be a 
potent inhibitor of 5-lipoxygenase (5-L O X ) ,   a   k e y   e n-
zyme  in  the  biosynthesis  of  leukotrienes  from  ara-
chidonic  acid  in  the  cellular  inflammatory  cascade 
[12,13]. 5-Loxin® is a novel B. serrata extract enriched 
to  30%  AKBA  (US  Patent  publication  no.: 
2004/0073060A1).  Affimatrix  gene  chip  analysis 
demonstrated  that  5-Loxin®  can potently inhibit tu-
m o r   n e c r o s i s   f a c t o r   α   ( T N F α )   i n d u c e d   g e n e   expression 
of matrix metalloproteinases (MMPs), adhesion mo-
lecules  such  as  intercellular  adhesion  molecule-1 
(ICAM-1)  and  vascular  cell  adhesion  molecule-1 
(VCAM-1); and mediators of apoptosis in human mi-
crovascular  endothelial  cells  [14,  15].  Cell  based  in 
vitro  studies  suggest  that  5-Loxin®  can  inhibit 
pro-inflammatory  cytokines  such  as  tumor  necrosis 
factor-α,  interleukin-1 β   [ 1 6 ] .   I n   t h e   c a r r a g e e-
nan-induced inflammation model, 5-Loxin® treatment 
yielded  significant  improvement  in  paw  inflamma-
tion in albino Wistar rats. 5-Loxin® also exhibited sig-
nificant Anti-arhtritic efficacy in FCA induced model 
of Sprague-Dawley rats [14, 15]. Extensive acute and 
dose  dependent  subchronic  safety  studies  on  rats 
demonstrated that 5-Loxin® is safe even at dose levels 
2,0 0 0   t o   3 , 0 0 0   t i m e s   h i g h e r   t h a n   t h e   h u m a n   e q u i v a-
lence dose [17]. In addition, 5-Loxin® w a s   f o u n d   t o   b e  
n o n   g e n o t o x i c   a s   p e r   t h e   s t a n d a r d   A M E S   b a c t e r i a l  
reverse mutation assay, chromosomal aberration test 
in Chinese hamster cells and mouse peripheral blood 
micronucleus assay [18-21] The efficacy and tolerabil-
i t y   o f   5 -Loxin®  was  assessed  in  a  previous  double 
blind placebo controlled clinical study. The supple-
mentation of 5-Loxin® w a s   w e l l   t o l e r a t e d   a n d   i t s   e f f i-
cacy against osteoarthritis was found to be statistically 
significant. The dose dependent efficacy of 5-Loxin® 
was assessed against pain, joint stiffness, mobility and 
a   c a r t i l a g e   d e g r a d i n g   e n z y m e   M M P -3   i n   O A   s u b j e c t s  
[22]. Aflapin® is a novel synergistic composition de-
rived from Boswellia serrata gum  resin (Indian Patent 
Application  No.  2229/CHE/2008).  Interestingly  it 
w a s   f o u n d   t h a t   t h e   o r a l   b i o a v a i l a b i l i t y   o f   A K B A   f r o m  
Aflapin®  w a s   b e t t e r   c o m p a r e d   t o   t h a t   o f   5 -Loxin®. 
Aflapin  exhibited  better  5-lipoxygenase  inhibitory 
activity and MMP-3 inhibition. Various in vitro and In 
vivo studies were  performed  to  compare  efficacy  of 
Aflapin and 5-Loxin®. These studies proved Aflapin 
t o   b e   m o r e   e f f i c a c i o u s   c o m p a r e d   t o   5 -Loxin® (to  be 
presented in a separate communication). The broad 
spectrum safety of Aflapin was tested using a battery 
o f   s a f e t y   s t u d i e s   c o n d u c t e d   a c c o r d i n g   t o   O E C D  
g u i d e l i n e s   a n d   i t   w a s   f o u n d   t o   b e   s a f e   [ 2 3 ] .   A l t h o u g h  
a significant number of clinical study reports support 
the anti-inflammatory and anti-arthritic properties of 
Boswellia  extract  [24-27],  no  human  clinical  studies 
were  done  to  prove  the  efficacy  and  tolerability  of 
Aflapin in osteoarthritis. Hence in the present clinical 
s t u d y   w e   s o u g h t   t o   e v a l u a t e   t h e   c o m p a r a t i v e   e f f i c a c y  
and  tolerability  of  5-Loxin®  and  Aflapin®  in  the 
treatment of OA of the knee.  
Materials and Methods 
Study materials 
BE-30 (5-Loxin
) is a novel Boswellia serrata ex-
tract  standardized  to  contain  at  least  30  percent 
3-O-Acetyl-11-keto-β-boswellic acid (AKBA) using a 
selective enrichment process (Indian patent # 205269). 
The process involves selective enrichment of AKBA 
while  simultaneously  suppressing  the  concentration 
of triterpene compounds that are less active and those 
that  antagonize  the  activity  of  AKBA.  Aflapin  is  a Int. J. Med. Sci. 2010, 7 
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novel  synergistic  composition  containing  B.  serrata 
extract selectively enriched with AKBA and B. serrata 
non-volatile  oil.  The  non-volatile  oil  was  prepared 
using  a  special  process  (PCT  application  # 
PCT/IN2009/000505) involving selective removal of 
Boswellic acids followed by removing volatiles under 
h i g h   v a c u u m .   T h e   c o m p o s i t i o n   w a s   s t a n d a r d i z e d   t o  
contain at least 20% AKBA. 
Study design 
T h i s   t r i a l   w a s   p e r f o r m e d   a t   A l l u r i   S i t a r a m a   R a j u  
Academy  of  Medical  Sciences  (ASRAM),  Eluru, 
A n d h r a   P r a d e s h ,   I n d i a   f r o m   J u l y   2 0 0 8   t o   D e c e m b e r  
2008  (clinical  trial  registration  number: 
ISRCTN80793440). The study protocol was evaluated 
and  approved  by  the  ASRAM  Institutional  Review 
B o a r d   ( I R B ) .   A n   o v e r v i e w   o f   t h e   c l i n i c a l   s t u d y   i s   p r o-
vided in Figure  1.   B r i e f l y ,   1 8 6   s u b j e c t s   o u t   o f   2 8 3   a t-
tending the orthopaedic outpatient department of the 
A S R A M   h o s p i t a l   w e r e   s e l e c t e d   i n   t h e   f i r s t   p h a s e   o f   t h e  
s c r e e n i n g   p r o c e d u r e ,   b a s e d   o n   t h e   s i g n s ,   s y m p t o m s  
a n d   r a d i o l o g i c a l   c h a n g e s   c o n s i s t e n t   w i t h   O A .   A   t otal 
o f   6 0   s u b j e c t s   s u f f e r i n g   f o r   m o r e   t h a n   3   m o n t h s   w i t h  
medial tibio-femoral  OA  were  selected  using  inclu-
sion/exclusion  criteria  summarized  in  Table  1.  All 
s u b j e c t s   s i g n e d   t h e   I R B   a p p r o v e d   c o n s e n t   f o r m .   S u b-
jects, who were otherwise healthy, were aged 40 years 
o r   o l d e r   a n d   h a d   a   d i a g n o s i s   o f   O A ,   f u l f i l l i n g   t h e  
American College of Rheumatology classification cri-
t e r i a   [ 4 ] .   A f t e r   r e c r u i t m e n t ,   t h e   s u b j e c t s   w e r e   r a n-
d o m l y   d i s t r i b u t e d   i n t o   t h r e e   g r o u p s .   T h e   d e m o-
graphic data and baseline characteristics are summa-
rized in Table 2. 
 
 
Figure 1: Flow chart of the subjects who participated in the clinical trial. Evaluations of physical activity and pain scores, 
serum biochemistry, hematology, and urine biochemistry were done at baseline (day 0) and on days 7, 30, 60 and 90 during 
follow up.  
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Table 1: Inclusion/exclusion criteria 
Criteria  Details 
 
Inclusion  Subjects must understand risks and benefits of the protocol and be able to give informed consent 
Male and female subjects aged 40 to 80 years 
Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test 
result 
Unilateral or bilateral osteoarthritis of the knee for more than 3 months 
Visual analogue scale score during the most painful knee movement between 40 and 70 mm after 7 days of withdrawal of 
usual medication 
Lequesne's Functional Index score greater than 7 points after 7 days of withdrawal of usual medication 
Ability to walk 
Availability for the duration of the entire study period 
Exclusion  History of underlying inflammatory arthropathy or severe rheumatoid arthritis 
Hyperuricaemia (>440 μmol/l) and/or past history of gout 
Recent injury in the area affected by osteoarthritis of the knee (past 4 months) and expectation of surgery in the next 4 months 
Intra-articular corticosteroid injections within the preceding 3 months 
Hypersensitivity to nonsteroidal anti-inflammatory drugs, abnormal liver or kidney function tests, history of peptic ulceration 
and upper gastrointestinal hemorrhage, congestive heart failure, hypertension, cancer, hyperkalaemia 
Major abnormal findings on complete blood count, history of coagulopathies, hematological or neurological disorders 
High alcohol intake (>2 standard drinks per day) 
Pregnant, breastfeeding, or planning to become pregnant during the study 
Use of concomitant prohibited medication other than ibuprofen 
Obesity (body mass index > 30 kg/m2) 
 
Table 2: Demographic data and baseline characteristics of the subjects 
Characteristics  Placebo 
(n = 19) 
100 mg/day 5-Loxin® (n = 19)  100 mg/day Aflapin® 
(n = 19) 
Sex (male/female; n)  9/10  3/16  7/12 
Age (years)  52.4 ± 7.5  51.6 ± 9.9  53.2 ± 7.9 
Body weight (kg)  62.4 ± 14.9  57.7 ± 10.5  59.1 ± 7.4 
Body mass index (kg/m2)  25.3 ± 4.4  25.1 ± 3.8  25.2 ± 3.0 
Visual analog score   47.7 ± 6.5  48.2 ± 6.1  47.7 ± 7.3 
Lequesne's Functional Index  12.3 ± 2.8  12.4 ± 2.6  12.0 ± 2.4 
WOMAC scores 
Pain subscale  44.7 ± 11.5  46.1 ± 7.6  45.0 ± 13.3 
Stiffness subscale  39.5 ± 11.2  39.5 ± 11.2  39.5 ± 13.3 
Function subscale  42.0 ± 10.3  43.1 ± 7.8  42.0 ± 8.4 
 
 
Before study enrollment, subjects were required 
to be taking an NSAID at prescription strength for at 
least 30 days or acetaminophen 1,200 to 4,000 mg/day 
o n   a   r e g u l a r   b a s i s   ( a t   l e a s t   2 5   o f  t h e   p r e c e d i n g   3 0   d a y s )  
with  a  history  of  therapeutic  benefit.  Eligibility  re-
quires  subjects  to  meet  specific  flare  criteria  upon 
medication  washout.  At  screening,  subjects  had  to 
d e m o n s t r a t e   a   v i s u a l   a n a l o g   s c a l e   ( V A S )   s c o r e   b e-
t w e e n   4 0   a n d   7 0   m m   d u r i n g   t h e  most  painful  knee 
movement,  and  Lequesne's  Functional  Index  (LFI) 
s c o r e   g r e a t e r   t h a n   7   p o i n t s   a f t e r   7 -day withdrawal of 
usual medication. 
A total of 60 selected subjects with symptoms of 
m o d e r a t e   t o   m i l d   O A   w e r e   r e c r u i t e d   i n t o   t h e   s t u d y .  
E a c h   s u b j e c t   w a s   r a n d o m l y   a s s i g n e d   t o   a   t r e a t m e n t  
group using a randomization table generated using 
v a l i d a t e d   c o m p u t e r   s o f t w a r e   C O D E ;   I D V ,   G a u t i n g ,  
Germany. The clinical trial pharmacist and statistician 
ensured that treatment codes remained confidential. 
The subjects were distributed into three groups: pla-
cebo (n=20); 5-L o x i n ®   g r o u p ,   i n   w h i c h   s u b j e c t s   r e-
ceived  50  mg  encapsulated  5-Loxin®  twice  daily 
(n=20); and Aflapin group, in which subjects received 
50  mg  encapsulated  Aflapin®  twice  daily  (n=20). 
S u b j e c t s   i n   t h e   p l a c e b o   g r o u p   r e c e i v e d   t w o   c a p s u l e s   o f  
similar  color,  taste  and  appearance  but  filled  with 
suitable  exicipient.  Each  subject  completed  a  ques-
tionnaire, providing details regarding demographics, 
medical history and nutritional status, at the baseline 
evaluation and during the follow-up  evaluations  on 
days 7, 30, 60 and 90. At the baseline evaluation, and 
at each visit during the 90-day follow up period,  all Int. J. Med. Sci. 2010, 7 
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subjects were assessed for pain and physical function 
using  validated  pain  scores.  Various  parameters  of 
serum biochemistry, hematology and urine analysis 
were carried out on each evaluation day. Safety was 
monitored  by  clinical  and  laboratory  assessments 
conducted  during  the  study  visits  and  sub-
ject-reported adverse experiences. 
Functional disability and pain score evaluation 
Functional disability was assessed by the inves-
t i g a t o r s   a t   b a s e l i n e   a n d   o n   e a c h   f o l l o w -up visit (days 
7, 30, 60 and 90). Questionnaire-based assessment of 
pain, stiffness and physical function were done using 
the Western Ontario and McMaster Universities Os-
teoarthritis Index (WOMAC) index [28], LFI [29] and 
VAS  [30].  The  WOMAC  index  produces  scores  for 
three subscales: pain, stiffness and physical function. 
T h e   p a i n ,   s t i f f n e s s   a n d   f u n c t i o n   s u b s c a l e s   o f   t h e  
WOMAC were normalized to a scale of 0 to 100 units 
( N U )   [ 3 1 ] .   T h e   p a i n   s u b s c a l e   w a s   t h e   a v e r a g e   o f   t h e  
first five questions of WOMAC and measured using 
t h e   N U   s c a l e   f r o m   0   ( ' n o pain') to 100 ('extreme pain') 
f o r   e a c h   q u e s t i o n .   T h e   s t i f f n e s s   s u b s c a l e   w a s   t h e   a v-
e r a g e   o f   q u e s t i o n s   6   a n d   7 ,   m e a s u r e d   u s i n g   t h e   N U  
s c a l e   f r o m   0   ( ' n o   s t i f f n e s s ' )   t o   1 0 0   ( ' e x t r e m e   s t i f f n e s s ' )  
for each question. The physical function subscale was 
the average of questions 8 through 24 of the WOMAC 
a n d   m e a s u r e d   b y   N U   s c a l e   f r o m   0   ( ' n o   d i f f i c u l t y ' )   t o  
100 ('extreme difficulty') for each question. Analyses 
of  these  end-points  were  based  upon  the 
time-weighted average change from baseline over 90 
days.  
Hematological and biochemical evaluations 
For assessment of safety of 5-Loxin® and  Afla-
pin®,  several  parameters  were  evaluated  in  serum, 
u r i n e   a n d   w h o l e   b l o o d   o f   a l l   s u b j e c t s   a t   e a c h   v i s i t   o f  
t h e   s t u d y   d u r a t i o n .   S e r u m   b i o c h e m i c a l   p a r a m e t e r s  
and hematological parameters were measured using 
an automated analyzer (HumaStar 300) and a hema-
tological  counter  (Humacount,  Human,  Wiesbaden, 
G e r m a n y ) .   T h e   u r i n e   a n a l y s i s   w a s   c a r r i e d   o u t   u s i n g  
UroColor™10 Dip Sticks and Urometer 600 (Standard 
Diagnostics,  Kyonggi-do,  Korea)  and  by  sediment 
analysis using microscopy.  
In vitro studies to identify mechanisms of actions 
of Aflapin: Effect on expression of ICAM-1 and 
MMP3 
Adhesion  molecule  (ICAM-1)  expression  on 
endothelial  cells:  20,000  Endothelial  cell  (HDMEC, 
Lonza Inc., USA) per well in quadruplicate wells were 
treated  with  medium,  vehicle,  TNFα  (20ng/ml), 
TNFα (20ng/ml) with 5-Loxin® or Aflapin® (4µg/ml 
e a c h )   f o r   2 4   h o u r   t h e n   I C A M -1 ELISA was performed 
o n   f i x e d   c e l l s   o f   t h e s e   w e l l s   a s   p e r   o u r   e s t a b l i s h e d  
protocol [32].  
Effect on secretion of MMP3 in TNFα induced 
human chondrocyte: Human primary Chondrocytes 
( H C H )   w a s   p r o c u r e d   f r o m   P r o m o   C e l l   G m b H   ( H e i-
delberg, Germany). HCH cells were cultivated in the 
growth  medium  (Ready-to-u s e ;   P r o m o   C e l l ,   C a t a l o g  
number  C-27101)  supplemented  with  Supplement 
Mix  (Promo  Cell,  Catalog  number  C-39635).  Equal 
n u m b e r   o f   H C H   c e l l s   w a s   p l a t e d   i n   e a c h   w e l l   o f  
96-well cell culture plate. Cells were treated with 5 
n g / m l   o f   T N F α   i n   p r e s e n c e   o r   a b s e n c e   o f   d i f f e r e n t  
concentrations of 5-Loxin® or Aflapin for 24h. Vehicle 
control cultures received 0.01% DMSO (v/v). MMP-3 
was quantitatively measured in the cell culture su-
pernatant by human MMP-3   E I A   k i t   ( R & D   S y s t e m s ,  
USA) following manufacturer’s instructions.  
Rescue medication 
Subjects were prescribed ibuprofen 400 mg tab-
l e t s   ( m a x i m u m   4 0 0   m g   t h r i c e   d a i l y ;   t o t a l   1 , 2 0 0   m g )   a s  
r e s c u e   a n a l g e s i a   d u r i n g   t h e   s t u d y   b a s e d   o n   p a i n   i n-
tensity reported to the study physician by the patient. 
However,  the  subjects  were  instructed  not  to  take 
m e d i c i n e   a t   l e a s t   3   d a y s   b e fore each evaluation. No 
other pain relieving interventions were allowed dur-
ing the study period.  
Statistical analysis 
Detailed statistical analyses were performed us-
i n g   S A S   s o f t w a r e   t o   e v a l u a t e   t h e   e f f i c a c y   o f   5 -Loxin® 
and Aflapin® i n   c o m p a r i s o n   w i t h   t h e  placebo group in 
terms of improvement in pain and physical function 
scores at baseline and on days 7, 30, 60 and 90 of 
treatment and serum MMP-3 levels at baseline and on 
d a y   9 0   o f   t r e a t m e n t .   P a i r -w i s e   c h a n g e s   w e r e   e x-
amined by carrying out a least significant difference 
t e s t   f o r   a l l   p o s s i b l e   p a i r s .   T h e   s i g n i f i c a n c e   o f   t h e   e f-
f e c t s   o f   t h e   t r e a t m e n t   g r o u p s   w a s   c o m p a r e d   b y   u s i n g  
one-w a y   a n a l y s i s   o f   v a r i a n c e   ( A N O V A )   f o l l o w e d   b y  
Tukey's  multiple  comparison  tests.  Results  with 
P<0.05 are considered statistically significant. This is a 
three-arm  (5-Loxin®,  Aflapin®  and  placebo),  rando-
m i z e d ,   d o u b l e -blind, placebo-controlled, single-centre 
t r i a l   c o n d u c t e d   o v e r   9 0   d a y s .   T h e   t r i a l ' s   p r i m a r y   o b-
jective was to determine the effects of 5-Loxin® and 
Aflapin® on pain, physical function and joint stiffness. 
For power calculations, the estimates for variability 
a n d   a s s u m e d   m e a n   c h a n g e s   f o r   e a c h   t r e a t m e n t   g r o u p  
w e r e   b a s e d   o n   r e s u l t s   f r o m   p r e v i o u s   p l a c e-
bo-c o n t r o l l e d   s t u d i e s   o f   c e l e c o x i b ,   e t o r i c o x i b   a n d   r o-
fecoxib  conducted  in  subje c t s   w i t h   O A   [ 3 3 -36].  We 
believe that an intervention that gives an average im-
provement of mean change ± 1 standard deviation, Int. J. Med. Sci. 2010, 7 
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r a t h e r   t h a n   m e a n   c h a n g e   a l o n e   w i l l   p r o v i d e   r e s u l t s   o f  
g r e a t e r   s i g n i f i c a n c e   [ 3 7 ] .   O u r   t r i a l   i s   d e s i g n e d   t o   h a v e  
more than 80% power to detect a situation in which 
either active drug dosage yields an improvement to at 
least mean change ± 0.9 standard deviation, under a 
conservative  assumption,  and  we  tested  differences 
between  groups  in  mean  improvement  using 
ANOVA  (α=0.05,  two-sided).   W i t h   2 0   s u b j e c t s   p e r  
g r o u p ,   w e   w o u l d   h a v e   a   9 3 %   c h a n c e   o f   o b s e r v i n g   a t  
l e a s t   o n e   e x a m p l e   o f   a n y   s i d e   e f f e c t   o c c u r r i n g   i n   1 0 %  
or more of the patient population at a specific dosage.  
Results 
Baseline characteristics 
Descriptive  statistics  comparing  demographic 
variables, baseline disease characteristics and baseline 
outcome measures (LFI, VAS, WOMAC pain, function 
and  stiffness  sub-s c o r e s )   a r e   p r o v i d e d   i n   T a b l e   2 .  
Overall, the treatment groups receiving 5-Loxin® 100 
mg/day, n=19, Aflapin® 100 mg/day, n=19 and  pla-
cebo  n=19,  were  similar  with  respect  to  age,  Body 
M a s s   I n d e x   a n d   p a i n   s e v e r i t y   ( T a b l e   2 ) .   T h e   s u b j e c t s  
were randomly distributed into three groups.  
Clinical efficacy 
We compared the scores between the treatment 
g r o u p s   o b t a i n e d   a t   d a y   9 0 .   B o t h   t h e   treatments with 
5-Loxin® and Aflapin® conferred clinically and statis-
tically  significant  improvements  in  pain  scores  and 
physical ability scores in OA subjects between base-
line and day 90 (Table 3). Tukey's multiple compari-
son  test  revealed  statistically  significant  improve-
ments by 31.6% (P=0.006), 30.3% (P=0.009) and 42.2% 
(p=0.006) in VAS, WOMAC pain, and WOMAC stiff-
ness  scores,  respectively,  in  the  100  mg  5-Loxin® 
t r e a t e d   g r o u p   i n   c o m p a r i s o n   w i t h   t h e   p l a c e b o   g r o u p  
(Table  3).  Improvements  by  18.35%  (P=0.060)  and 
21.25% (P=0.078) in LFI and WOMAC functional abil-
ity  scores,  respectively  were  also  achieved  in  the 
5-Loxin®  g r o u p   ( T a b l e   3 ) .   I n   c o m p a r i s o n   w i t h   t h e  
placebo  group,  the  Aflapin®  100  mg  treated  group 
also exhibited statistically significant improvements 
in all parameters tested (Table 3). The Aflapin group 
showed  improvements  by  47.3%  (P<0.0001),  35.8% 
(P=0.0004),  61.7%  (P<0.0001),  60.1%  (P=0.0001)  and 
49.4%  (P=0.0001)  in  VAS,  LFI,  WOMAC  pain, 
WOMAC  stiffness  and  WOMAC  functional  ability 
scores,  respectively.  It  is  worth  noting  that  both 
5-Loxin®  and  Aflapin®  treatment  groups  exhibited 
improvement  in  pain  scores  and  physical  ability 
scores as early as 7 days after the start of treatment, 
and  these  indices  continued  to  improve  throughout 
the 90 days of treatment (Figure 2) .   A f t e r   7   d a y s ,   t h e  
5-Loxin® treatment group exhibited 8.09% (P=0.002), 
8.68%  (P=0.031)  and  8.35%  (p=0.015)  reductions  in 
VAS, WOMAC pain and WOMAC function respec-
tively,  compared  with  the  corresponding  baseline 
s c o r e s .   A f t e r   7   d a y s ,   t h e   A f l a p i n   t r e a t m e n t   g r o u p   e x-
hibited  12.8%  (P=0.0004),  9.17%  (P=0.003),  11.78% 
(P=0.012), 18.48% (P=0.012) and 10.24% (p=0.005) re-
ductions in VAS, LFI WOMAC pain, WOMAC stiff-
ness  and  WOMAC  function  scores  respectively, 
compared to the corresponding baseline scores  (Fig-
ure 2). 
 
T a b l e   3 : Student's t-t e s t   ( p a i r e d )   a n a l y s e s   f o r   c o m p a r i s o n   o f   t h e   s c o r e s   o b t a i n e d   f r o m   t h e   A f l a p i n   a n d   5 -Loxin groups at day 
90 
  n  Baseline  Day 90  95% CI (versus pla-
cebo) 
p 
Mean  SD  Mean  SD 
Visual analogue scale score 
  Placebo  19  47.7  6.5  38.3  9.0  34.0, 42.7  0.0013 
  5-Loxin 100 mg/day  19  48.2  6.1  26.2  16.5  18.2, 34.1  <0.0001 
  Aflapin 100 mg/day  19  47.7  7.3  20.2  12.3  14.2, 26.1  <0.0001 
Lequesne's Functional Index 
  Placebo  19  12.3  2.8  10.9  3.0  9.4, 12.3  0.0496 
  5-Loxin 100 mg/day  19  12.4  2.6  8.9  3.7  7.1, 10.7  <0.0001 
  Aflapin 100 mg/day  19  12.0  2.4  7.0  2.6  7.1, 9.6  <0.0001 
WOMAC pain subscale 
  Placebo  19  44.7  11.5  36.3  10.5  31.2, 41.4  0.0021 
  5-Loxin 100 mg/day  19  46.1  7.6  25.3  17.2  17.0, 33.6  <0.0001 
  Aflapin 100 mg/day  19  45.0  13.3  13.9  8.3  10.0, 17.9  <0.0001 
WOMAC stiffness subscale 
  Placebo  19  39.5  11.2  29.6  9.5  25.0, 34.2 p  0.0059 
  5-Loxin 100 mg/day  19  39.5  11.2  17.1  16.8  9.0, 25.2  0.0001 
  Aflapin 100 mg/day  19  39.5  13.3  11.8  12.8  5.7, 18.0  <0.0001 Int. J. Med. Sci. 2010, 7 
 
http://www.medsci.org 
372 
  n  Baseline  Day 90  95% CI (versus pla-
cebo) 
p 
Mean  SD  Mean  SD 
WOMAC function subscale 
  Placebo  19  42.0  10.3  32.0  10.8  26.8, 37.2  0.0025 
  5-Loxin 100 mg/day  19  43.1  7.8  25.2  15.0  17.9, 32.4  <0.0001 
  Aflapin 100 mg/day  19  42.0  8.4  16.2  8.1  12.3, 20,1  <0.0001 
CI, confidence interval; WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index. 
 
 
Figure 2: Bar diagrams represent the mean scores of (a) visual analog scale (VAS) (a); Lequesne's Functional Index (LFI) (b); 
Western  Ontario  and  McMaster  Universities  Osteoarthritis  Index  (WOMAC)-pain  (c);  WOMAC-stiffness  (d);  and 
WOMAC-function (e) i n   p l a c e b o ,   1 0 0   m g /   d a y   5 -Loxin
® and 100 mg/day Aflapin
® groups, respectively. 1   t o   5 , represent days 
of evaluations such as day 0,   d a y   7 ,   d a y   3 0 ,   d a y   6 0   a n d   d a y   9 0 , respectively. Each bar represents mean ± standard deviation. 
In comparison with corresponding baseline data, the change in scores in the treatment groups was tested for significance 
using Tukey's multiple comparison test; * p<0.05; ** p<0.005. Int. J. Med. Sci. 2010, 7 
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Aflapin inhibits secretion of MMP-3 in 
TNFα-induced human primary chondrocytes 
I n   O A ,   t h e   l o s s   o f   c o l l a g e n   f r o m   a r t i c u l a r   c a r t i-
lage is proportional to the disease severity (38). Under 
the  influence  of  pro-inflammatory  cytokines,  in-
creased production and secretion of collagenases such 
as MMP-3, MMP-13 is the crucial event for enhanced 
collagen  degradation  in  OA  [39].  Therefore,  we 
sought to evaluate whether 5-Loxin  and  Aflapin  can 
modulate  MMP-3  secretion  in  TNFα,   a   p o t e n t   p r o - 
inflammatory  cytokine  induced  human  primary 
chondrocytes.  Figure  3  shows  a  steep  increase  in 
MMP-3   s e c r e t i o n   i n   T N F α-induced chondrocytes and 
dose-dependent  inhibition  of  MMP-3  secretion  in 
5-Loxin  and  Aflapin  treated  cultures.  Interestingly, 
we observed, Aflapin (IC50 at 18.5 µg/ml) provided 
(41.36%)  better  efficacy  than  5-Loxin  (IC50  at  31.71 
µg/ml)  in  inhibiting  MMP-3  secretion  from 
TNFα-induced human chondrocytes.  
Aflapin inhibits ICAM-1 expression in activated 
endothelial cells 
OA is a degenerative joint disorder. However, 
t h e r e   a r e   m i g r a t i o n s   o f   i n f l a m m a t o r y   c e l l s   i n   t h e  
synovial fluid. Adhesion molecule expression on en-
dothelial cells helps in the diapedesis of these cells. 
Therefore,  in  order  to  determine  whether  5-Loxin® 
and Aflapin® treatments can ameliorate the ICAM-1 
expression,  we  evaluated  the  ICAM  levels  on 
HDMEC. Figure 4 depicts that 5-Loxin® and Aflapin® 
significantly reduce TNFα  induced  ICAM-1  expres-
s i o n   ( p < 0 . 0 1 ,   s t u d e n t   t -test).  Interestingly,  Aflapin® 
shows  more  capability  to  reduce  ICAM-1  secretion 
than that of 5-Loxin®.  
Biochemical evaluations 
As  a  part  of  the  safety  evaluation,  laboratory 
tests were performed to evaluate different biochemi-
cal parameters (serum and urine) and hematological 
parameters.  The  significance  of  the  differences  be-
t w e e n   b a s e l i n e   a n d   9 0   d a y s   w a s   t e s t e d   b y   u s i n g   r e-
p e a t e d   m e a s u r e s   A N O V A .   T h e   f   r a t i o   i s   c o n s i d e r e d  
significant if P<0.05.  Although  minor  changes  were 
observed in some of the parameters, they remained 
within  the  normal  laboratory  range.  Statistical  ana-
lyses of these parameters did not indicate any signif-
icant  changes.  Similarly,  no  significant  changes  in 
hematological and urinary parameters were observed 
i n   t h e   a c t i v e   t r e a t m e n t   g r o u p s   w h e n   c o m p a r e d   t o   t h e  
placebo  (data  not  shown).  These  findings  further 
demonstrate  the  safety  of  5-Loxin®  and Aflapin® in 
humans. 
Adverse Events and Dropouts 
D u r i n g   t h e   c o u r s e   o f   t h e   9 0 -day study, no major 
adverse events were reported. However, acidity was 
reported  as  a  minor  adverse  event  by  two  subjects 
d u r i n g   t h e   s t u d y ;   o n e   e a c h   f r o m   p l a c e b o   a n d   A f l a p i n  
supplemented groups, respectively.  
T h r e e   s u b j e c t s   o n e   f r o m   e a c h   p l a c e b o ,   5 -Loxin® 
and Aflapin® supplemented groups were dropped out 
f r o m   t h e   s t u d y   d u e   t o   t h e i r   u n -availability during the 
entire study period.  
 
 
Figure 3: Aflapin and 5-Loxin inhibit matrix metalloproteinase-3   s e c r e t i o n   f r o m   T N F α-induced human primary chon-
drocytes. Line diagram represents MMP-3 concentrations in the culture supernatants of chondrocytes treated with 5 ng/ml 
of human recombinant TNFα in presence or absence of different doses of either 5-Loxin or Aflapin as indicated. Vehicle 
control cultures received 0.01% DMSO. Each data point represents the mean of quadruplicate wells.  Int. J. Med. Sci. 2010, 7 
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Figure 4: Aflapin and 5-Loxin inhibit TNFα-induced ICAM-1 expression on human dermal microvascular endothelial cells 
(HDMEC). Bar diagrams represent the ICAM-1 expression on HDMEC treated with 20ng/ml of human recombinant TNF-α 
in presence or absence of either 5-L o x i n   ( 4 µ g / m l )   o r   A f l a p i n   ( 4 µ g / m l )  as indicated. Vehicle control cultures received 0.01% 
DMSO. Each experiment is done in quadruplicate wells. The results are expressed as the mean±SD of five experiments in 
quadruplicate wells. 5-Loxin and Aflapin significantly inhibits ICAM-1 expression induced by TNF-α (p<.01, student t-test). 
 
Discussion 
T h i s   i s   t h e   f i r s t   c l i n i c a l   s t u d y   t o   e v a l u a t e   t h e   e f-
ficacy of  Aflapin® i n   O A   s u b j e c t s .   A f l a p i n   i s   a   n o v e l  
synergistic composition comprising AKBA enriched 
B. serrata e x t r a c t   a n d   n o n   a c i d i c   g u m   e x t r a c t   o f   B. ser-
rata.   I n   a   b a t t e r y   o f   p r e c l i n i c a l   s t u d i e s   d e s i g n e d   i n   in 
vitro cellular models and in vivo animal models, Afla-
pin  exhibited  significantly  better  anti-inflammatory 
activities  in  comparison  with  5-Loxin®  (Data  to  be 
presented in a separate communication). 5-Loxin® is a 
Boswellia serrata extract standardized to 30% AKBA. Its 
multidirectional  activities  related  to  an-
ti-inflammatory  efficacies  obtained  in  appropriate 
cellular, animal models and in human subjects have 
established that 5-Loxin® is a potent dietary supple-
m e n t   f o r   t h e   m a n a g e m e n t   o f   i n f l a m m a t o r y   d i s e a s e s  
such  as  osteoarthritis  [14-2 2 ] .   I n   a   s e r i e s   o f   e xperi-
ments designed in in vitro cellular and in vivo animal 
models, Aflapin showed significantly better efficacy 
in  comparison  with  5-Loxin®.  In  addition,  Aflapin 
exhibited  better  AKBA  bioavailability  than  5-Loxin® 
in Wistar rat model. Broad spectrum safety of Aflapin 
was  also  established  in  a  battery  of  acute  and 
sub-acute  toxicity  studies  in  rat  and  rabbits.  These 
findings altogether motivated us to evaluate efficacy 
of Aflapin in comparison with 5-Loxin®  against  os-
teoarthritis in human subjects. In the present 90-day 
clinical study, we assessed the efficacy and tolerability 
of Aflapin in comparison with 5-Loxin® in OA sub-
j e c t s .   P a i n ,   s t i f f n e s s   o f   j o i n t s ,   r e d u c e d   j o i n t   m o v e m e n t  
and physical disability are the major clinical manife-
stations of OA [1,40,41]. Our study demonstrates that 
Aflapin potentially improves pain, joint stiffness and 
physical function in OA subjects (Figure  2) .   I n   o r d e r  
to check improvements in the treatment groups, we 
compared  the  data  for  all  parameters  between  the 
baseline and day 90. Paired t-test revealed that both 
treatment groups showed statistically significant im-
provements in all parameters. 
Compared to  the  placebo,  5-Loxin® supplemen-
t a t i o n   f o r   9 0   d a y s ,   s i g n i f i c a n t l y   r e d u c e d   V A S ,  
WOMAC-pain,  WOMAC-stiffness  (Table  3),  which 
are  consistent  with  our  previous  observations  [22]. 
Whereas,  Aflapin  supplementation  for  90  days,  re-
sulted in significant reduction   i n   a l l   p a i n   s c o r e s   t e s t e d  
in comparison with placebo. These findings suggest 
t h a t   A f l a p i n   h a s   b e t t e r   t h e r a p e u t i c   e f f i c a c y   a g a i n s t   O A  
compared to 5-Loxin®. We observed that, in compar-
ison with baseline, there were downward trends in 
VAS score and WOMAC sco r e s   i n   t h e   p l a c e b o   g r o u p .  
We believe that this might be partly attributable to the 
placebo effect [42,43] manifested while administering 
t h e   q u e s t i o n n a i r e s   t o   p l a c e b o   s u b j e c t s   a n d   p a r t l y   d u e  
t o   t h e   c o n s u m p t i o n   o f   i b u p r o f e n   a s   r e s c u e   m e d i c a t i o n  
b y   m o r e   s u b jects  in  the  placebo  group  during  the 
study. It  is  noteworthy  that  5-Loxin® possesses sig-
n i f i c a n t   e f f i c a c y   i n   l o w e r i n g   V A S   s c o r e   b y   8 . 0 9 %  
(P=0.022), WOMAC pain score by 8.68% (0.031) and 
WOMAC  function  score  by  8.35%  (P<0.015)  in  OA 
s u b j e c t s   a s   e a r l y   a s   7   days  after  the  initiation  of 
treatment. In comparison, Aflapin showed significant 
reduction  in  all  the  pain  scores  assessed  including 
V A S   s c o r e   b y   1 2 . 8 %   ( P=0.0004),  LFI  score  by  9.17% 
(P=0.003),  WOMAC  pain  score  by  11.78%  (P=0.012), 
WOMAC  stiffness  score  by  18.48%  (P=0.012)  and Int. J. Med. Sci. 2010, 7 
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WOMAC function score by 10.24% (P=0.005) (Figure 
2). These findings therefore indicate that 5-Loxin® and 
Aflapin® confers prompt and significant pain relief, 
improvement in physical ability and quality of life in 
OA subjects. However, Aflapin showed better reduc-
t i o n   i n   a l l   t h e   t e s t e d   p a i n   s c o r e s   a n d   h e n c e   c a n   b e  
considered superior to 5-Loxin®. 
 Pathogenesis  of  osteoarthritis  is  a  complex 
process.  These  include  mechano-transduction,  the 
interplay between metalloproteases (MMP3, MMP13), 
protease inhibitors and cytokines on cartilage degra-
dation and mechanisms of cartilage repair [40,44,45]. 
MMP-3   i s   o v e r -expressed in OA and cause degenera-
t i o n   o f   c a r t i l a g e   t i s s u e   [ 4 4 , 4 5 ] .  Cytokines act via auto-
crine  and  endocrine  functions  to  alter  cartilage  ho-
meostasis. Interleukin-1 (IL-1) and TNF-α are perhaps 
the best characterized cytokines for cartilage degra-
dation (46,47). They are synthesized by chondrocytes 
a n d   F L S .   T h e s e   c y t o k i n e s   a c t   i n   v a r i o u s   w a y s   i n   t h e  
pathogenesis of OA such as inhibition of synthesis of 
type 2 (articular) cartilage and activation of catabolic 
metalloproteases  including  MMP-3  which  plays  a 
c r i t i c a l   r o l e   i n   c a r t i l a g e   d e g r a d a t i o n   [ 4 4 , 4 5 ] .   A   r o l e   o f  
synovitis in OA can’t be disregarded either. It is a well 
established clinical observation that pain and swelling 
in OA improves for months following intra-articular 
corticosteroid injection. In addition, histologic studies 
suggest that localized inflammatory changes charac-
terized by foci of inflammatory cells occur in up to 
50% of O A   p a t i e n t s   [ 4 8 ] .   I n   t h i s   s t u d y   t o   f i n d   o u t  
p o s s i b l e   m e c h a n i s m   o f   a c t i o n s   o f   A f l a p i n   w e   c a r r i e d  
out  in vitro s t u d i e s   t o   e v a l u a t e   w h e t h e r   A f l a p i n   c a n  
inhibit metalloprotease secretion or influence the in-
flammatory  component  of  osteoarthritis.  We  ob-
served:  (1)  Aflapin  inhibits  TNFα  induced  MMP-3 
secretion in chondrocytes; (2) Aflapin inhibits TNFα 
induced expression of ICAM-1 in endothelial cells.   
Overall,  the  foregoing  data  together  demon-
strates  the  better  ability  of  Aflapin  compared  with 
5-Loxin® in terms  of reducing the pain, improving 
physical  function,  quality  of  life  and  joint  health. 
Presumably these improvements might occur through 
down regulation of cartilage degrading enzymes such 
as  MMP-3   i n   O A   s u b j e c t s .   T h e   p r e s e n t   s t u d y   a l s o  
demonstrates no major changes in the hematological 
parameters,  serum  biochemical  parameters  and  in 
urine analysis in the treatment groups compared to 
p l a c e b o .   I n   a d d i t i o n ,   n o   m a j o r   a d v e r s e   e f f e c t   w a s   r e-
p o r t e d   b y   t h e   s u b j e c t s   i n   t h e   t r e a t m e n t   g r o u p s .   T a k e n  
together, these observations further demonstrate that 
5-Loxin®  and  Aflapin®  are  potentially  safe  in  the 
t r e a t m e n t   o f   O A   i n   h u m a n s   a n d   m o r e   s p e c i f i c a l l y  
Aflapin®  i s   m o r e   e f f i c a c i o u s   i n   t h e   m a n a g e m e n t   o f  
osteoarthritis than 5-Loxin®. 
Conclusion 
I n   s u m m a r y ,   t h e   p r e s e n t   s t u d y   p r o vides  the 
e v i d e n c e   i n   s u p p o r t   o f   t h e   p o t e n t i a l   e f f i c a c y   a n d   t o-
lerability of 5-Loxin®  and Aflapin®  in  subjects  with 
OA;  5-Loxin®  and  Aflapin  significantly  improved 
joint  function.  Aflapin  exhibited  better  therapeutic 
efficacy over 5-Loxin® at 100 mg/day; it reduces pain 
rapidly, as early as after 1 week of treatment. Fur-
thermore, in vitro studies also provide evidences that 
compared to 5-Loxin, Aflapin is capable of inhibiting 
cartilage degrading enzyme MMP-3 and has the po-
tential to regulate the inflammatory component in by 
inhibiting  ICAM-1.  Most  importantly,  we  have  ob-
served that 5-Loxin® and Aflapin® a r e   s a f e   f o r   h u m a n  
consumption,  even  for  long  term  supplementation. 
5-Loxin® and Aflapin® are promising alternative the-
rapeutic  options,  that  may  be  used  as  nutritional 
supplements for management of OA.  
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